Análisis de la acción Electra Therapeutics, Inc. Common stock (ETRA)

$8.980

+0.485 (+5.40%)Al cierre

Loading chart…

Máximo: 9.210
Apertura: 8.360
Precio medio ponderado por volumen: 8.85
Volumen: 177.30K
Capitalización: —
Mínimo: 8.360
Importe: 1.57M
EV/EBITDA, TTM: 0.00

Electra Therapeutics Inc is a United States-based clinical- stage biotechnology company. The Company is developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Its ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells and precisely depletes pathological immune cells.

electra-therapeutics.com

Análisis de IA of Electra Therapeutics, Inc. Common stock (ETRA)

Vender

Electra Therapeutics, Inc. is not a good buy right now due to significant declines in its stock price and lack of positive financial indicators. The stock has fallen 41.93% year-to-date and 24.59% over the last 20 days, indicating a persistent downward trend. Furthermore, the company has a price-to-book ratio of -21.69, which suggests severe financial distress. Without any earnings or positive analyst ratings to support a recovery, the risks outweigh potential rewards.

Métricas de valoración

El PER previsto actual de Electra Therapeutics, Inc. Common stock (ETRA) es 0.00, frente a su media de 5 años de .

PER previsto

Media 5A P/E

P/E actual

0.00

EV/EBITDA previsto

Media 5A EV/EBITDA

EV/EBITDA actual

0.00

Precio/ventas previsto

Media 5A P/S

P/S actual

0.00

Cronología de eventos

2026-09-21 (ET)